Purchase this article with an account.
N. K. Yadav, S. Prasad, S. Natesh, P. Srinivasan, V. Kemmanu, B. K. Shetty; Intravitreal Bevacizumab (Avastin) for Choroidal Neovascularization Secondary to Pathologic Myopia. Invest. Ophthalmol. Vis. Sci. 2009;50(13):2279.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the safety and efficacy of intravitreal Avastin in the treatment of myopic choroidal neovascular membrane (mCNV).
18 eyes of 17 patients, receiving intravitreal Avastin for mCNV were retrospectively analyzed for changes in the best corrected visual acuity(BCVA),Fluorescein angiography(FFA),and optical coherence tomography(OCT).
18 eyes of 17 patients were followed up for a mean period of 9.27(range 6-15) months. The Mean spherical equivalent refractive error of the 18 eyes was -14.75 D (range, -6 to -24 D).The mean ± standard deviation (SD) logarithm of the minimum angle of resolution (logMAR) BCVA at baseline was 0.28±0.20 (snellen equivalent,20/80). At the last follow up the mean logMAR BCVA improved to 0.42 (snellen equivalent,20/40;p<0.003).vision improved by a mean of 1.7 (range, 0-6) lines on the snellen visual acuity chart. The mean ± SD baseline central retinal thickness (CRT) of 288±60.36µm reduced to 209µm ± 46.91µm (p<0.0001).The mean number of injections per eye was 2.8 (range1-5). Leakage from the mCNV had resolved in 15 of the 18 eyes and was reduced in 3 eyes. No ocular or systemic adverse affects were noted.
Intravitreal Avastin is a safe and effective treatment option for mCNV, resulting in improved visual acuity and central retinal thickness. Larger prospective controlled trials with a longer follow up are needed to study the optimal treatment regime, safety and dosage.
This PDF is available to Subscribers Only